Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Company profile
Ticker
ALLO
Exchange
Website
CEO
David D. Chang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
ALLO stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
28 Feb 23
8-K
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Departure of Directors or Certain Officers
3 Jan 23
8-K
Other Events
29 Nov 22
S-3ASR
Automatic shelf registration
2 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
2 Nov 22
8-K
Other Events
6 Oct 22
Transcripts
ALLO
Earnings call transcript
2022 Q4
28 Feb 23
ALLO
Earnings call transcript
2022 Q3
3 Nov 22
ALLO
Earnings call transcript
2022 Q2
10 Aug 22
ALLO
Earnings call transcript
2022 Q1
5 May 22
ALLO
Earnings call transcript
2021 Q4
24 Feb 22
ALLO
Earnings call transcript
2021 Q3
5 Nov 21
ALLO
Earnings call transcript
2021 Q2
5 Aug 21
ALLO
Earnings call transcript
2021 Q1
6 May 21
ALLO
Earnings call transcript
2020 Q4
28 Feb 21
ALLO
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
4
David D Chang
16 Mar 23
4
ERIC THOMAS SCHMIDT
16 Mar 23
4
ALISON MOORE
16 Mar 23
4
Veer Bhavnagri
16 Mar 23
4
Veer Bhavnagri
14 Feb 23
SC 13G
Chang David D
13 Feb 23
SC 13G/A
Belldegrun Arie
13 Feb 23
SC 13G
VANGUARD GROUP INC
9 Feb 23
SC 13G
STATE STREET CORP
3 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 72.20 mm | 72.20 mm | 72.20 mm | 72.20 mm | 72.20 mm | 72.20 mm |
| Cash burn (monthly) | 4.15 mm | 9.28 mm | 32.12 mm | 27.95 mm | 20.70 mm | 18.38 mm |
| Cash used (since last report) | 10.99 mm | 24.59 mm | 85.09 mm | 74.04 mm | 54.82 mm | 48.67 mm |
| Cash remaining | 61.20 mm | 47.61 mm | -12.89 mm | -1.84 mm | 17.37 mm | 23.52 mm |
| Runway (months of cash) | 14.7 | 5.1 | -0.4 | -0.1 | 0.8 | 1.3 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 170 |
| Opened positions | 24 |
| Closed positions | 44 |
| Increased positions | 63 |
| Reduced positions | 54 |
| 13F shares | Current |
|---|---|
| Total value | 679.03 bn |
| Total shares | 147.12 mm |
| Total puts | 62.50 k |
| Total calls | 36.10 k |
| Total put/call ratio | 1.7 |
| Largest owners | Shares | Value |
|---|---|---|
| PFE Pfizer | 22.03 mm | $200.71 mm |
| TPG GP A | 18.72 mm | $117.73 bn |
| STT State Street | 9.17 mm | $57.66 bn |
| BLK Blackrock | 8.89 mm | $55.90 bn |
| Vanguard | 7.27 mm | $45.70 bn |
| Seaview Trust | 7.04 mm | $105.05 mm |
| T. Rowe Price | 5.94 mm | $37.32 bn |
| Capital International Investors | 5.31 mm | $33.40 bn |
| Primecap Management | 4.94 mm | $31.10 bn |
| Belldegrun Arie | 4.71 mm | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Mar 23 | Veer Bhavnagri | Common Stock | Payment of exercise | Dispose F | No | No | 5.67 | 23,628 | 133.97 k | 556,049 |
| 14 Mar 23 | Moore Alison | Common Stock | Payment of exercise | Dispose F | No | No | 5.5071 | 8,351 | 45.99 k | 114,637 |
| 14 Mar 23 | Schmidt Eric Thomas | Common Stock | Payment of exercise | Dispose F | No | No | 5.47 | 35,879 | 196.26 k | 304,345 |
| 14 Mar 23 | Chang David D | Common Stock | Payment of exercise | Dispose F | No | No | 5.56 | 22,340 | 124.21 k | 2,269,447 |
| 13 Feb 23 | Veer Bhavnagri | Common Stock | Sell | Dispose S | No | Yes | 6.85 | 3,000 | 20.55 k | 577,677 |
News
Allogene Therapeutics's Return On Capital Employed Insights
3 Mar 23
What 10 Analyst Ratings Have To Say About Allogene Therapeutics
2 Mar 23
Goldman Sachs Maintains Buy on Allogene Therapeutics, Lowers Price Target to $31
2 Mar 23
JMP Securities Maintains Market Perform on Allogene Therapeutics, Lowers Price Target to $19
2 Mar 23
Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $28
1 Mar 23
Press releases
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
14 Mar 23
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
8 Mar 23
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
2 Mar 23
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
28 Feb 23
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm
25 Jan 23